Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
Pioneering Regenerative Medicine
Without Immunosuppression

We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.

iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.


iTOL-101 and iTOL-102: Developing a Potential Cure for Type 1 Diabetes
iTOL-101 utilizes allogeneic cadaveric pancreatic islets in combination with iTOL-100 and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, Insulin-Dependent Diabetes, pancreatic islets derived from cadavers co-implanted with iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our iTOL-102 program leverages significant advancements in stem cells to derive human pancreatic islets which allows an inexhaustible supply of insulin-producing cells and is being developed as a potential cure for Type 1 Diabetes.
Development Pipeline

1: Development of iTOL-401 is subject to the entry of a license agreement with Georgia Tech Research Corporation
We Were 1 of 3 Companies Selected to Participate in the Disruptive Healthcare
Technology Showcase at the US Capitol on June 12, 2023.

Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Appoints Former FDA Senior Executive Wayne Pines to the Board of Directors
MIAMI, FL / ACCESS Newswire / June 25, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced the appointment of Wayne Pines to the...
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, February 25, 2025. NLS Pharmaceutics Ltd. (Nasdaq: NLSP”)...
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, December 19, 2024. NLS Pharmaceutics Ltd. (Nasdaq:...